

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 September 2020 (10.09.2020)



(10) International Publication Number
WO 2020/180257 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) A61K 39/395 (2006.01)
G01N 33/53 (2006.01) A61P 25/16 (2006.01)

(21) International Application Number:

PCT/SG2020/050113

(22) International Filing Date:

06 March 2020 (06.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201902046S 07 March 2019 (07.03.2019) SG

(71) Applicant: SINGAPORE HEALTH SERVICES PTE LTD [SG/SG]; 31 Third Hospital Avenue #03-03, Singapore 168753 (SG).

(72) Inventors: CHAN, Lai Ling Sharon; c/o National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433 (SG). TAN, Eng King; c/o National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433 (SG).


(74) Agent: YUSARN AUDREY; 24 Raffles Place, #27-01 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: THREONINE166 AND SERINE189 OF RUBICON RUN DOMAIN AS LRRK2 KINASE INHIBITION TARGET SITES

Figure 7



(57) Abstract: Methods of detecting the phosphorylation at Threonine 166 and/or Serine 189 of a Rubicon protein to identify a subject having a disease associated with Leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease using an antibody. Also disclosed are methods of treating the same using inhibitors to block the interaction of LRRK2 with Threonine 166 and/or Serine 189 of the Rubicon protein.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*